Toggle navigation
COVID-19
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
2023 ASH
2023 SABCS
24th SUO Annual Meeting
2023 NCCN Annual Congress: Hematologic Malignancies
IASLC 2023 WCLC
Calendar
View All
Topics
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
Cardio-oncology
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
Advertisement
Departments
ASCO Plenary Series
Adolescent and Young Adult Oncology
Announcements
Art of Oncology
ASCO State Affiliates
At Microphone 1
The Big Casino
Book Reviews
Clinical Trials Resource Guide
Direct From ASCO
Diversity in Oncology
Education in Oncology
End-of-Life Oncology
Expert’s Corner
FDA Update
Geriatrics for the Oncologist
Health-Care Policy
Hematology Expert Review
In Memoriam
Inside the Black Box
Integrative Oncology
In the Clinic
In the Literature
In the News
Journal Spotlight
Law and Ethics
Letters to the Editor
Living a Full Life
OCE Insights
Oncology Worldwide
Perspectives
Palliative Care in Oncology
Patient’s Corner
Pioneers in Oncology
Prevention in Oncology
Profiles
Psychosocial Oncology
Special Reports
Through the Lens of Oncology History
Women in Oncology
Advertisement
Advertisement
Dec
11
Today In Oncology
Novel Selective Biomarker Tool May Help Select Effective Targeted Therapies in Patients With Metastatic Breast Cancer
Patients With HR-Positive Breast Cancer May Use Fertility Preservation and Assisted Reproductive Technologies Without Increased Risk of Recurrence
Novel Targeted Therapies May Benefit Patients With Metastatic HR-Positive/HER2-Negative Breast Cancer
Younger Postmenopausal Patients With Early-Stage Breast Cancer May Be Able to Safely Omit Adjuvant Radiotherapy
Tucatinib Plus T-DM1 May Benefit Patients With Advanced or Metastatic HER2-Positive Breast Cancer
View More
Advertisement